BACKGROUND: High-level MYCN amplification (MNA) is associated with poor outcome and unfavorable clinical and biological features in patients with neuroblastoma. To the authors' knowledge, less is known regarding these associations in patients with low-level MYCN copy number increases. METHODS: In this retrospective study, the authors classified patients has having tumors with MYCN wild-type tumors, MYCN gain (2-4-fold increase in MYCN signal compared with the reference probe), or MNA (>4-fold increase). Tests of trend were used to investigate ordered associations between MYCN copy number category and features of interest. Log-rank tests and Cox models compared event-free survival and overall survival by subgroup. RESULTS: Among 4672 patients, 3694 (79.1%) had MYCN wild-type tumors, 133 (2.8%) had MYCN gain, and 845 (18.1%) had MNA. For each clinical/biological feature, the percentage of patients with an unfavorable feature was lowest in the MYCN wild-type category, intermediate in the MYCN gain category, and highest in the MNA category (P<.0001), except for 11q aberration, for which the highest rates were in the MYCN gain category. Patients with MYCN gain had inferior event-free survival and overall survival compared with those with MYCN wild-type. Among patients with high-risk disease, MYCN gain was associated with the lowest response rate after chemotherapy. Patients with non-stage 4 disease (according to the International Neuroblastoma Staging System) and patients with non-high-risk disease with MYCN gain had a significantly increased risk for death, a finding confirmed on multivariable testing. CONCLUSIONS: Increasing MYCN copy number is associated with an increasingly higher rate of unfavorable clinical/biological features, with 11q aberration being an exception. Patients with MYCN gain appear to have inferior outcomes, especially in otherwise more favorable groups. Cancer 2017;123:4224-35. V C 2017 American Cancer Society.
INTRODUCTION
Neuroblastoma, the most common extracranial solid tumor affecting children, is remarkable for its extreme clinical heterogeneity. Although the 5-year overall survival (OS) rate has increased over the past several decades, generalizing OS for all patients with neuroblastoma can be misleading. Studies of several known prognostic factors in neuroblastoma have revealed that some have a greater impact on outcome than others, and some are only prognostic in subsets of patients. [1] [2] [3] [4] Most notably, MYCN gene amplification (MNA) has proven to be an independent prognostic factor for identifying rapid tumor progression and predicting poor prognosis irrespective of age and clinical stage of disease. 5, 6 To the best of our knowledge, MNA, which occurs in approximately 16% of cases of neuroblastoma, 7 was one of the first tumor-derived genetic markers that was shown to be of clinical and prognostic value. Current guidelines for the assignment of risk group used by the International Neuroblastoma Risk Group (INRG) and the Children' Oncology Group (COG) heavily weigh MYCN amplification. 1, 8 In addition to an established correlation with prognosis, MNA also is known to be associated with important clinical and biological features. 7 MNA is more common in patients with adrenal primary tumors and less common in those with thoracic primary tumors. 4, 7 There is a strong association between MNA and other tumor biologic and genomic features, such as unfavorable histology, 9 ,10 diploidy, [11] [12] [13] high mitotic karyorrhectic index (MKI), 14 and loss of heterozygosity (LOH) at 1p. [15] [16] [17] [18] [19] MYCN copy number is a discrete variable, but groups have applied cutpoints that define specific tumors as amplified versus nonamplified. In the COG, MNA is defined using fluorescence in situ hybridization (FISH) as a >4-fold increase in MYCN signal number compared with centromeric reference probe, a definition that is consistent with international consensus but without a clear biological rationale for an exact threshold of 4-fold. 20 The COG further categorizes MYCN copy number into 4 groups: 1) wild-type (<2-fold increase in MYCN signal); 2) MYCN gain (2-4-fold increase); 3) low-level MNA (5-10-fold increase); and 4) high-level MNA (>10-fold increase). Likewise, the International Collaboration for Neuroblastoma Research (SIOPEN) group classifies tumors with a 2-fold to 4-fold increase as "MYCN gain (inconclusive)." 21 The majority of cases with a >2-fold increase in MYCN signal have high-level MNA (>10-fold increase), and thus less is known regarding patients with MYCN gain or low-level MNA. Two prior studies reported that MYCN gain was associated with inferior outcomes compared with patients with wild-type tumors, 22 ,23 although a third study reported superior outcomes for this group. 24 It is interesting to note that MYCN gain appears to be positively associated with 11q aberration, whereas MNA is inversely associated with 11q aberration, suggesting that the relationship of MYCN copy number with other clinical or biological features may be complex. 22, 23 To understand the prognostic impact of MYCN copy number and provide new insights into the relationship between MYCN copy number and other clinical and biological features of neuroblastoma, we conducted a comprehensive analysis of a large cohort of patients with known MYCN copy number. We also attempted to determine whether the relationship between MYCN copy number and these clinical and biological features demonstrated trends with increasing copy number.
MATERIALS AND METHODS

Patients
Patients were eligible for inclusion in the analytic cohort if they enrolled in the COG Neuroblastoma Biology study ANBL00B1 from November 1, 2007 to February 28, 2016 before treatment; had a confirmed diagnosis of neuroblastoma or ganglioneuroblastoma (intermixed or nodular); and had satisfactory centralized test results reported for MYCN. Consent was obtained at time of enrollment to ANBL00B1. This retrospective analysis was deemed exempt from further review by the Dana-Farber Cancer Institute Office for Human Research Studies.
Primary Predictor Variable
Our primary predictor variable was MYCN copy number category. MYCN copy number was determined by interphase FISH performed in the Neuroblastoma Reference Laboratory at Nationwide Children's Hospital using frozen or paraffin-embedded tumor tissue or bone marrow with confirmed neuroblastoma cells. FISH was performed using a dual-color probe (Abbott Molecular, Abbott Park, Illinois), with a CEP2 centromeric probe as reference. MYCN wild-type was defined as a <2-fold increase in MYCN signal and MYCN gain was defined as a 2-fold to 4-fold signal gain in 20% of cells compared with the reference probe. MNA was defined as a >4-fold increase in MYCN signal compared with a reference probe, with lowlevel MNA defined as a 5-fold to 10-fold increase in signal and high-level MNA as >10-fold increase in signal. Because the focus of this report was MYCN copy number, heterogeneous MYCN amplification (the presence of MNA in <20% of tumor cell nuclei) was not evaluated further herein.
Outcome Variables
Clinical variables of interest included sex, age, International Neuroblastoma Staging System (INSS) stage, 25 COG risk group, 26 primary tumor site, lactate dehydrogenase (LDH) level (dichotomized at group median), and ferritin level (dichotomized at group median). Biological variables of interest, determined centrally by the Neuroblastoma Reference Laboratory and pathologists, included ploidy (hyperdiploidy indicated any DNA index >1.0), 1p LOH, 11q aberration (unbalanced LOH 15 ), International Neuroblastoma Pathology Classification (INPC) histologic classification, 10 MKI, and grade of differentiation. Clinical outcomes were end-induction response to chemotherapy, event-free survival (EFS), and overall survival (OS). Response to induction chemotherapy was defined using the International Neuroblastoma Response Criteria 25 and was only available for patients with highrisk disease treated on COG protocols ANBL0532 27 and ANBL12P1. 28 For patients with metaiodobenzylguanidine (MIBG)-avid disease, MIBG imaging was a standard component of response assessment. EFS was defined as time from diagnosis to the first episode of disease recurrence, disease progression, death, or secondary malignancy; patients without an event were censored at the date of last contact. OS was defined as time from diagnosis to death; surviving patients were censored at the date of last contact.
Statistical Analyses
Associations between MYCN copy number categories and clinical and biological features were assessed using Cochran-Armitage tests for trend, 29 testing the null hypothesis of no linear trend against an alternative of a linear trend, with at least 1 strict inequality between groups. Chi-square tests or Fisher exact tests were used to conduct 2 group comparisons between clinical and biological features.
Tests of association between end-induction response and MYCN copy number category were performed using a Cochran-Armitage test for trend. EFS and OS were estimated as per the Kaplan-Meier method and survival curves compared between MYCN copy number categories using log-rank tests.
Cox proportional hazards models tested the prognostic strength of MYCN copy number category in a univariate model and in multivariable models using standard neuroblastoma risk factors ( Table 2 for details regarding the 10 patients with low-level MNA).
The characteristics of the overall cohort ( Clinical features were found to be significantly associated with MYCN copy number in the full cohort (Table 1) . We observed significant trends for an increasing percentage of patients with unfavorable clinical features with increasing MYCN copy number category. Some of the most prominent differences were noted in the percentage of patients with INSS stage 4 disease (32% for MYCN wild-type, 63% for MYCN gain, and 78% for MNA; P<.0001) and the percentage of patients with elevated LDH (39% for MYCN wild-type, 46% for MYCN gain, and 90% for MNA; P<.0001). In addition, trends in primary adrenal tumor site (30% for MYCN wild-type, 45% for MYCN gain, and 48% for MNA; P<.0001) reinforced prior findings that primary adrenal tumors are more frequently associated with an increased MYCN copy number. 4 When this comparison was restricted to patients with MYCN gain versus MNA, it was not found to be statistically significant. In contrast, we observed that as MYCN copy number increased, the percentage of patients with a primary thoracic tumor decreased (23% for MYCN wild-type, 12% for MYCN gain, and 3% for MNA; P<.0001).
We next compared clinical features by MYCN copy number in clinically relevant cohorts. Among patients with high-risk, stage 4 disease, the majority of the tests of trend of MYCN copy number with clinical features were again significant (Table 2) 1878 (51) 75 (56) 503 (60) <.0001
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Biological Features Differ According to MYCN Copy Number
Several strong associations between unfavorable biological features and higher MYCN copy number were detected in the full cohort (Table 1) , including 1p LOH, unfavorable histology, high MKI, and undifferentiated/poorly differentiated grade. However, the highest rate of aberration at 11q was observed in patients with MYCN gain (37%) compared with the other groups (16% for MYCN wildtype and 7% for MNA tumors). Comparing MYCN gain and MNA, some of the most prominent differences in biological features were for 1p LOH (40% in patients with MYCN gain vs 71% in those with MNA) and for high MKI (15% in patients with MYCN gain vs 68% for patients with MNA).
In our subgroup analyses of patients with highrisk, INSS stage 4 disease (Table 2 ) and of patients with non-stage 4 disease (Table 3) , we observed similar findings for 1p LOH and MKI as were observed in the full cohort. However, the association with histology observed in the full cohort was observed only among patients with non-stage 4 disease, perhaps due to the small numbers of patients with high-risk, stage 4 disease with favorable histology. It is interesting to note that a similar pattern for aberration at 11q was observed among patients with non-stage 4 disease, as was noted in the full cohort, with patients with MYCN gain having the highest percentage of tumors with an 11q aberration (24%). In contrast, among patients with high-risk stage 4 disease, patients with MYCN wild-type and MYCN gain tumors had similar rates of 11q aberration (49% and 47%, respectively), with patients with MNA again found to have very low rates of 11q aberration (9%). 
Clinical Outcomes Differ According to MYCN Copy Number
In the full cohort, EFS differed significantly according to MYCN copy number category (Fig. 1A) . Specifically, the 5-year EFS rate for patients with wild-type disease was 76.4% (95% confidence interval [95% CI], 73.8%-79.0%) compared with 57.4% for patients with MYCN gain (95% CI, 39.6%-75.2%) and 48.1% for patients with MNA (95% CI, 42.3%-54%) (P<.0001). We also investigated specific subgroups of patients (those with high-risk, stage 4 disease; those with non-stage 4 disease; and high-risk patients) and again observed significant differences in EFS according to MYCN copy number (P values were adjusted for nonproportional hazards) (Figs. 1B-1D ) (see Supporting Information Table 3 for comparisons of patients with MYCN gain vs MNA and for patients with MYCN gain vs MYCN wild-type).
OS likewise differed significantly according to MYCN copy number category ( Figs. 2A-2E ). In the full cohort, the 5-year OS rate for patients with wild-type disease was 86.1% (95% CI, 84.0%-88.2%) compared with 66.3% (95% CI, 49.5%-83.2%) for patients with MYCN gain and 55.2% (95% CI, 49.4%-60.9%) for patients with MNA (P<.0001, adjusted for nonproportional hazards) (Fig. 2A) . We observed that subgroups with nonstage 4 disease or non-high-risk disease were at an increased risk of death in the presence of MYCN gain, with OS significantly lower than that for patients with MYCN wild-type tumors in both subgroups (unadjusted P<.0001 and .0017, respectively) (Figs. 2D and 2E) (see Supporting Information Table 3 ). Deaths among patients with MYCN gain in the non-stage 4 disease subgroup or in the non-high-risk subgroup were noted exclusively within the first year after diagnosis (Figs. 2D and 2E ). In contrast, among patients with high-risk disease, OS was not significantly different between patients with MYCN gain versus those with MYCN wild-type tumors (see Supporting Information Table 3 ).
In Cox models of EFS and OS, after controlling for age, INSS stage, ploidy, MKI, and grade of differentiation, the outcome for patients with MYCN gain was no longer statistically significantly lower compared with patients with MYCN wild-type tumors ( Table 4 ). The presence of MNA remained prognostic of lower EFS and OS. Among highrisk patients (subgroups of high-risk patients or patients with stage 4, high-risk disease), we observed similar findings. Among patients with more favorable features (nonstage 4 disease subgroup and non-high-risk subgroup), we demonstrated that patients with MYCN gain had inferior OS even after controlling for other risk factors (adjusted P 5 .0262 and .0331, respectively).
In the full cohort and in the cohort with non-stage 4 disease, we constructed separate Cox models of EFS and OS controlling for 11q status to determine whether the aforementioned associations between MYCN gain and prognosis were potentially confounded by the association between MYCN gain and 11q aberration. In both cohorts, the presence of MYCN gain remained prognostically independent of 11q status (see Supporting Information Table 4 ).
To provide context for these observed differences, we investigated potential differences in induction response rates by copy number category for high-risk patients treated on COG protocols ANBL0532 and ANBL12P1 (Table 5 ). Data were available for 687 patients (364 patients with MYCN wild-type tumors, 24 patients with MYCN gain tumors, and 299 patients with MNA). Of these, data represent end-induction response in 665 patients and mid-induction response in 22 patients who withdrew before end-induction. We found the highest response rate (partial response or better) among those with MYCN amplification (85.0%) and the lowest response rate among those with MYCN gain (62.5% in MYCN gain; P 5 .0004). Likewise, patients with MYCN-amplified disease had the highest complete response rate (25.1%), patients with MYCN gain had the lowest , it is important to understand the distribution of MYCN copy number in this disease and how clinical and biological features differ across copy number groups. Knowledge of differing prognosis according to MYCN copy number also may have therapeutic implications. The results of the current study demonstrate ordered associations between MYCN copy number and several clinical and biological features of neuroblastoma as well as an association between higher MYCN copy number and lower EFS and OS. The key findings of the current study include inferior outcomes in patients with MYCN gain in subgroups with otherwise more favorable features, the high rate of 11q aberration in tumors with MYCN gain, and the extreme rarity of lowlevel MNA.
The negative prognostic impact of MYCN gain may enable the identification of patients with non-high-risk disease who require therapy modification. Although EFS and OS differed significantly among MYCN copy number groups in the full cohort (Figs. 1A and 2A) , our multivariable and subgroup analyses indicated that the greatest impact was in the subgroups of patients with non-stage 4 disease and non-high-risk disease. We observed inferior OS for patients with MYCN gain compared with MYCN wild-type copy number in these 2 subgroups (Figs. 2D  and 2E ). However, we noted that the absolute difference in OS was relatively modest. The current study findings suggest that current management strategies may not be adequate for this unique subset of patients, although to the best of our knowledge, the etiology for these differences is not clear from our available data. Specifically, it is possible that the presence of MYCN gain confers a survival disadvantage directly by increasing the level of MYCN protein or MYCN-target genes, although to our knowledge prior studies have not consistently observed an increase in MYCN RNA with increasing MYCN copy number. 23, 30 Alternatively, it is possible that MYCN gain is a marker for gain of 2p and therefore a surrogate for propensity for segmental chromosomal aberrations. 31 The associations between both 11q (another segmental chromosomal aberration) and hyperdiploidy (in patients with non-stage 4 disease) and MYCN gain are consistent with this latter hypothesis. It is important to note that the presence of MYCN gain remained a significant predictor of EFS and OS after controlling for 11q status.
The current study findings regarding 11q aberration patterns support prior literature findings that 11q aberration has an inverse association with MNA. 15, 19 Based on this pattern, one might reasonably expect that tumors with MYCN gain also would have lower rates of 11q aberration. Two prior groups have reported higher rates of 11q aberration in tumors with MYCN gain, 22, 23 and we believe the results herein confirm and extend this finding. 32 These findings, together with those of the current study related to MYCN gain, suggest that a threshold level of increased MYCN copy number is required to disrupt let-7. It is possible that tumors with a MYCN copy number below this threshold are under genetic pressure to acquire other features, such as 11q aberration, that also disrupt this critical microRNA. Thus, the findings of the current study are consistent with the evolving understanding of key biological pathways of neuroblastoma oncogenesis.
The results of the current study demonstrate that the incidence of low-level MYCN amplification is exceedingly low (0.2%). To the best of our knowledge, the reason for this paucity of cases is not clear, but is consistent with different mechanisms leading to low-level copy number increases versus amplification. This epidemiologic finding provides a reason to suggest the consolidation of low-level and high-level MYCN amplification into 1 category, simply MYCN amplified. Aside from 11q aberration, the findings of the current study indicate that the presence of unfavorable clinical and biological features as well as poor prognosis follow ordered patterns according to increasing MYCN copy number category. Current FISH technology allows for the identification of distinct copy number values for MYCN if present in single digits; however, in the majority of cases of MNA, distinct numerical values are difficult to assign reliably. Furthermore, as more groups adopt technologies such as single-nucleotide polymorphism assays to detect MYCN copy number, the reliable identification of lower levels of MNA may be challenging. In addition, detection of heterogeneous levels of MNA, which have been the subject of other reports, 33 ,34 also will not be feasible.
A major strength of the current study was its large cohort of 4672 contemporary patients with available MYCN copy number data, compared with 659 patients for what to the best of our knowledge is the next largest series that has focused on patients with MYCN gain tumors. 23 Moreover, all patients underwent MYCN testing in a centralized laboratory using one methodology. As stated above, we were not able to evaluate copy number as a discrete, rather than ordinal, variable. We also note that these findings represent epidemiological associations that cannot address the underlying biology that leads to these observations. If our novel finding of lower response rates to conventional chemotherapy in patients with MYCN gain and high-risk disease is observed in future studies among patients with non-high-risk disease, this may suggest a possible mechanism for the inferior outcomes associated with MYCN gain in that population. We note that, to the best of our knowledge, the basis for this lower response rate in patients with MYCN gain is as yet unknown and merits further study, including the potential impact of 11q aberration on chemotherapy response. The lack of data for a subset of our outcome variables is another limitation of our work. Finally, future studies should investigate the heterogeneity of MYCN copy number alterations within the same tumor. This phenomenon occurs in <2% of patients with neuroblastoma, 33, 34 and was not investigated as part of the current study.
We believe the results of the current study add to our overall understanding of MYCN copy number and its association with key clinical, biological, and outcome variables. The current study findings demonstrate the rarity of low-level MYCN amplification, trends in associations between MYCN copy number and clinical and biological features, and evidence of a specific association between 11q aberration and MYCN gain. Further studies should be conducted to elucidate the biological basis for these associations. Moreover, the results of the current study suggest that the presence of MYCN gain may identify a group of patients with otherwise more favorable features who are at higher risk of early treatment failure.
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